Britain’s Indivior Plc., which is also evaluating a long-acting injectable in a late-stage study, received the U.S. FDA’s fast-track status on Thursday for the treatment.
Natalie Grover |
Britain’s Indivior Plc., which is also evaluating a long-acting injectable in a late-stage study, received the U.S. FDA’s fast-track status on Thursday for the treatment.
More than 10 years ago, I wrote a commentary in The Rheumatologist, called “Perils of Pain Meds,” about the over-prescribing of opioid analgesics for common causes of chronic noncancer pain, which was a major contributor to the opioid epidemic.1 Since that time, although there has been a greater than 20% decrease in opioid prescribing, the…
I have been listening to The Fighter Pilot Podcast because my fantasy career would have been to fly a jet fighter plane (not even remotely possible, given my constitution). I learned that when an aircraft accident occurs, a mishap board is convened, not to assign blame but to try to learn what went wrong and…
Treating patients with rheumatic disease for their addictions will also encourage patients to address their overall health conditions, resulting in better medical adherence…
CHICAGO—Although medical treatments for addiction have been proved effective, they are not used often enough, said Kenneth Stoller, MD, during a session at the 2019 ACR State-of-the-Art Clinical Symposium, held April 5–7. These treatments bring health benefits that extend beyond addiction, he said. Dr. Stoller, assistant professor of psychiatry and behavioral sciences at Johns Hopkins…